Eloxx Pharmaceuticals, Inc.
Eloxx Pharmaceuticals Announces Publication of Phase 2a Exaluren Data in Nonsense Mutation Alport Syndrome in the Journal of Clinical Investigation
First-in-human evidence of exaluren-mediated readthrough of collagen IV in patients with nonsense mutation Alport syndrome Kidney biopsies showed…
